Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study was conducted to compare the activities of erlotinib to that of intravenous,
platinum-based therapy in the treatment of non-small cell lung cancer (NSCLC). The goal of
this trial was to demonstrate clinical equivalence of erlotinib to platinum-based frontline
therapy, compared to historical controls.